Valuation Update With 7 Day Price Move • May 13
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to LK₨16.70, the stock trades at a trailing P/E ratio of 23.1x. Average trailing P/E is 14x in the Healthcare industry in Sri Lanka. Total returns to shareholders of 234% over the past three years. New Risk • Apr 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Sri Lankan stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (LK₨21.3b market cap, or US$66.9m). Valuation Update With 7 Day Price Move • Apr 21
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to LK₨13.50, the stock trades at a trailing P/E ratio of 18.7x. Average trailing P/E is 15x in the Healthcare industry in Sri Lanka. Total returns to shareholders of 141% over the past three years. Valuation Update With 7 Day Price Move • Mar 18
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to LK₨10.20, the stock trades at a trailing P/E ratio of 19.5x. Average trailing P/E is 13x in the Healthcare industry in Sri Lanka. Total returns to shareholders of 67% over the past three years. Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to LK₨14.50, the stock trades at a trailing P/E ratio of 27.7x. Average trailing P/E is 14x in the Healthcare industry in Sri Lanka. Total returns to shareholders of 138% over the past three years. Valuation Update With 7 Day Price Move • Oct 29
Investor sentiment improves as stock rises 32% After last week's 32% share price gain to LK₨13.50, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 13x in the Healthcare industry in Sri Lanka. Total returns to shareholders of 125% over the past three years. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to LK₨10.40, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 13x in the Healthcare industry in Sri Lanka. Total returns to shareholders of 68% over the past three years. Valuation Update With 7 Day Price Move • Sep 10
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to LK₨9.70, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 13x in the Healthcare industry in Sri Lanka. Total returns to shareholders of 59% over the past three years. Announcement • Sep 09
Nawaloka Hospitals PLC, Annual General Meeting, Sep 30, 2025 Nawaloka Hospitals PLC, Annual General Meeting, Sep 30, 2025, at 10:00 Sri Lanka Standard Time. New Risk • Aug 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Sri Lankan stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.8x net interest cover). Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (LK₨11.6b market cap, or US$38.2m). New Risk • Aug 21
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 87% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.8x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (LK₨10.7b market cap, or US$35.5m). Reported Earnings • Aug 17
First quarter 2026 earnings released: EPS: LK₨0.52 (vs LK₨0.09 in 1Q 2025) First quarter 2026 results: EPS: LK₨0.52 (up from LK₨0.09 in 1Q 2025). Revenue: LK₨2.96b (up 12% from 1Q 2025). Net income: LK₨734.7m (up 493% from 1Q 2025). Profit margin: 25% (up from 4.7% in 1Q 2025). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 31
Full year 2025 earnings released: EPS: LK₨0.24 (vs LK₨0.22 loss in FY 2024) Full year 2025 results: EPS: LK₨0.24 (up from LK₨0.22 loss in FY 2024). Revenue: LK₨11.1b (up 7.0% from FY 2024). Net income: LK₨344.4m (up LK₨649.1m from FY 2024). Profit margin: 3.1% (up from net loss in FY 2024). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 16
Third quarter 2025 earnings released: LK₨0.10 loss per share (vs LK₨0.07 profit in 3Q 2024) Third quarter 2025 results: LK₨0.10 loss per share (down from LK₨0.07 profit in 3Q 2024). Revenue: LK₨2.59b (down 6.7% from 3Q 2024). Net loss: LK₨141.2m (down 241% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings. Reported Earnings • Nov 16
Second quarter 2025 earnings released: EPS: LK₨0.53 (vs LK₨0.07 loss in 2Q 2024) Second quarter 2025 results: EPS: LK₨0.53 (up from LK₨0.07 loss in 2Q 2024). Revenue: LK₨3.08b (up 21% from 2Q 2024). Net income: LK₨223.3m (up LK₨323.3m from 2Q 2024). Profit margin: 7.2% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings. Announcement • Oct 10
Nawaloka Hospitals PLC, Annual General Meeting, Oct 30, 2024 Nawaloka Hospitals PLC, Annual General Meeting, Oct 30, 2024, at 10:00 Sri Lanka Standard Time. New Risk • Sep 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Sri Lankan stocks, typically moving 5.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.3x net interest cover). Share price has been highly volatile over the past 3 months (5.6% average weekly change). Minor Risk Market cap is less than US$100m (LK₨5.22b market cap, or US$17.3m). Reported Earnings • Aug 16
First quarter 2025 earnings released: EPS: LK₨0.09 (vs LK₨0.09 in 1Q 2024) First quarter 2025 results: EPS: LK₨0.09 (in line with 1Q 2024). Revenue: LK₨2.65b (up 1.2% from 1Q 2024). Net income: LK₨123.9m (up 2.9% from 1Q 2024). Profit margin: 4.7% (up from 4.6% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Reported Earnings • Jun 04
Full year 2024 earnings released: EPS: LK₨0.25 (vs LK₨1.73 loss in FY 2023) Full year 2024 results: EPS: LK₨0.25 (up from LK₨1.73 loss in FY 2023). Revenue: LK₨10.6b (up 14% from FY 2023). Net income: LK₨347.8m (up LK₨2.79b from FY 2023). Profit margin: 3.3% (up from net loss in FY 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance. Reported Earnings • Feb 16
Third quarter 2024 earnings released: EPS: LK₨0.07 (vs LK₨0.06 loss in 3Q 2023) Third quarter 2024 results: EPS: LK₨0.07 (up from LK₨0.06 loss in 3Q 2023). Revenue: LK₨2.78b (up 12% from 3Q 2023). Net income: LK₨100.1m (up LK₨191.3m from 3Q 2023). Profit margin: 3.6% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance. Board Change • Feb 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 5 highly experienced directors. 3 independent directors (7 non-independent directors). Independent Non-Executive Director Tissa Bandaranayake was the last independent director to join the board, commencing their role in 2009. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Jan 25
Nawaloka Hospitals PLC, Annual General Meeting, Feb 14, 2024 Nawaloka Hospitals PLC, Annual General Meeting, Feb 14, 2024, at 10:00 Sri Lanka Standard Time. Location: No. 23, Deshamanya H K Dharmadasa Mawatha Colombo 02 Sri Lanka Agenda: To receive and consider the report of the board of Directors on the affairs of the company and the financial statements for the year ended 31 March 2023 together with the report of Auditors thereon; to resolve in terms of Section 211 of the Companies Act No. 07 of 2007 to appoint/re-appoint Dr. Hewa Komanage Jayantha Dharmadasa (who has attained the age of 75 years) and who retires at the end of the Annual General Meeting, as a Director; to resolve in terms of Section 211 of the Companies Act No. 07 of 2007 to appoint/re-appoint Vidya Jyothi Professor Lal Chandrasena (who has attained the age of 77 years) and who retires at the end of the Annual General Meeting, as a Director; to re-elect Directors; to authorize the Board of Directors to determine and make donations to charities; and to consider other related matters. New Risk • Jun 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Sri Lankan stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). Earnings have declined by 2.2% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.6% average weekly change). Market cap is less than US$100m (LK₨5.78b market cap, or US$19.5m). Reported Earnings • Jun 02
Full year 2023 earnings released: LK₨0.64 loss per share (vs LK₨0.069 loss in FY 2022) Full year 2023 results: LK₨0.64 loss per share (further deteriorated from LK₨0.069 loss in FY 2022). Revenue: LK₨9.70b (down 37% from FY 2022). Net loss: LK₨902.5m (loss widened LK₨805.9m from FY 2022). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Reported Earnings • Feb 19
Third quarter 2023 earnings released: LK₨0.06 loss per share (vs LK₨0.38 profit in 3Q 2022) Third quarter 2023 results: LK₨0.06 loss per share (down from LK₨0.38 profit in 3Q 2022). Revenue: LK₨2.48b (down 34% from 3Q 2022). Net loss: LK₨91.1m (down 117% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Announcement • Jan 03
Nawaloka Hospitals PLC Elects Maithri (Maiya) Gunasekera as Director Nawaloka Hospitals PLC announced that at its 33rd Annual General Meeting held on 30th December 2022, approved the election of Dr. Maithri (Maiya) Gunasekera as a Director. Announcement • Dec 09
Nawaloka Hospitals PLC, Annual General Meeting, Dec 30, 2022 Nawaloka Hospitals PLC, Annual General Meeting, Dec 30, 2022, at 10:00 Sri Lanka Standard Time. Reported Earnings • Nov 17
Second quarter 2023 earnings released: LK₨8.00 loss per share (vs LK₨0.22 profit in 2Q 2022) Second quarter 2023 results: LK₨8.00 loss per share (down from LK₨0.22 profit in 2Q 2022). Revenue: LK₨2.34b (down 44% from 2Q 2022). Net loss: LK₨114.3m (down 137% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Independent Non-Executive Director Palitha Kumarasinghe was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 17
First quarter 2023 earnings released: LK₨0.15 loss per share (vs LK₨0.19 profit in 1Q 2022) First quarter 2023 results: LK₨0.15 loss per share (down from LK₨0.19 profit in 1Q 2022). Revenue: LK₨2.16b (down 37% from 1Q 2022). Net loss: LK₨208.7m (down 178% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment improved over the past week After last week's 21% share price gain to LK₨6.30, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 8x in the Healthcare industry in Sri Lanka. Total returns to shareholders of 57% over the past three years. Reported Earnings • Jun 02
Full year 2022 earnings released: EPS: LK₨0.61 (vs LK₨0.36 in FY 2021) Full year 2022 results: EPS: LK₨0.61 (up from LK₨0.36 in FY 2021). Revenue: LK₨13.1b (up 11% from FY 2021). Net income: LK₨854.5m (up 71% from FY 2021). Profit margin: 6.5% (up from 4.2% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 116% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • May 18
Investor sentiment improved over the past week After last week's 17% share price gain to LK₨7.00, the stock trades at a trailing P/E ratio of 6.7x. Average trailing P/E is 6x in the Healthcare industry in Sri Lanka. Total returns to shareholders of 75% over the past three years. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Independent Non-Executive Director Palitha Kumarasinghe was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment deteriorated over the past week After last week's 28% share price decline to LK₨5.60, the stock trades at a trailing P/E ratio of 5.4x. Average trailing P/E is 7x in the Healthcare industry in Sri Lanka. Total returns to shareholders of 37% over the past three years. Valuation Update With 7 Day Price Move • Mar 15
Investor sentiment deteriorated over the past week After last week's 15% share price decline to LK₨7.20, the stock trades at a trailing P/E ratio of 6.9x. Average trailing P/E is 8x in the Healthcare industry in Sri Lanka. Total returns to shareholders of 71% over the past three years. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment deteriorated over the past week After last week's 18% share price decline to LK₨8.40, the stock trades at a trailing P/E ratio of 8x. Average trailing P/E is 9x in the Healthcare industry in Sri Lanka. Total returns to shareholders of 91% over the past three years. Reported Earnings • Feb 17
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: LK₨0.38 (up from LK₨0.26 in 3Q 2021). Revenue: LK₨3.74b (up 42% from 3Q 2021). Net income: LK₨528.8m (up 47% from 3Q 2021). Profit margin: 14% (in line with 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 116% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment improved over the past week After last week's 19% share price gain to LK₨11.80, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 10x in the Healthcare industry in Sri Lanka. Total returns to shareholders of 157% over the past three years. Valuation Update With 7 Day Price Move • Sep 02
Investor sentiment improved over the past week After last week's 20% share price gain to LK₨8.30, the stock trades at a trailing P/E ratio of 10.9x. Average trailing P/E is 8x in the Healthcare industry in Sri Lanka. Total returns to shareholders of 80% over the past three years. Reported Earnings • Aug 18
First quarter 2022 earnings released: EPS LK₨0.19 (vs LK₨0.19 loss in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: LK₨3.42b (up 141% from 1Q 2021). Net income: LK₨266.6m (up LK₨538.4m from 1Q 2021). Profit margin: 7.8% (up from net loss in 1Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Jul 16
Non-Executive Director recently sold LK₨1.9m worth of stock On the 8th of July, Victor Ramanan sold around 300k shares on-market at roughly LK₨6.30 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Is New 90 Day High Low • Mar 05
New 90-day low: LK₨4.90 The company is down 11% from its price of LK₨5.50 on 04 December 2020. The Sri Lankan market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 5.0% over the same period. Reported Earnings • Feb 19
Third quarter 2021 earnings released: EPS LK₨0.26 (vs LK₨0.06 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: LK₨2.64b (up 10% from 3Q 2020). Net income: LK₨359.7m (up 351% from 3Q 2020). Profit margin: 14% (up from 3.3% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 10
New 90-day low: LK₨5.10 The company is down 9.0% from its price of LK₨5.60 on 12 November 2020. The Sri Lankan market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 16% over the same period. Announcement • Nov 24
Nawaloka Hospitals PLC, Annual General Meeting, Dec 16, 2020 Nawaloka Hospitals PLC, Annual General Meeting, Dec 16, 2020, at 10:00 Sri Lanka Standard Time. Location: at the Orchid Hall of the "BMICH" (Bandaranaike Memorial International Conference Hall) at Bauddhaloka Mawatha, Colombo Sri Lanka Agenda: To receive and consider the Report of the Board of Directors on the Affairs of the Company and the Financial Statements for the year ended 31st March 2020 together with the Report of Auditors thereon; to consider the re-election of directors; to authorise the Board of Directors to determine and make donations to charities; to re-appoint Messrs KPMG (Chartered Accountants) as Auditors of the Company and authorise the Board of Directors to determine their remuneration; and to transact any other business of which due Notice has been given. Reported Earnings • Nov 15
Second quarter 2021 earnings released: EPS LK₨0.03 The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: LK₨2.29b (up 2.9% from 2Q 2020). Net income: LK₨49.2m (up 20% from 2Q 2020). Profit margin: 2.1% (up from 1.8% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 86% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Oct 02
New 90-day high: LK₨4.10 The company is up 21% from its price of LK₨3.40 on 03 July 2020. The Sri Lankan market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 18% over the same period.